Jefferies Downgrades Corbus Pharmaceuticals (CRBP) to Hold, After Study Fails Endpoints
Tweet Send to a Friend
Jefferies analyst Maury Raycroft downgraded Corbus Pharmaceuticals (NASDAQ: CRBP) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
